Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?

Ann Hematol. 2014 Nov;93(11):1951-2. doi: 10.1007/s00277-014-2096-y. Epub 2014 May 7.

Authors

Matteo Molica¹, Alessandra Serrao, Roberta Saracino, Irene Zacheo, Christof Stingone, Giuliana Alimena, Massimo Breccia

Affiliation

¹ Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

PMID: 24801017
DOI: 10.1007/s00277-014-2096-y

No abstract available

Publication types

Case Reports
Letter
Review

MeSH terms

Endpoint Determination / standards*
Humans
Male
Middle Aged
Nitriles
Primary Myelofibrosis / diagnosis*
Primary Myelofibrosis / drug therapy*
Pyrazoles / therapeutic use*
Pyrimidines
Treatment Outcome

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib